India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz
This article was originally published in PharmAsia News
Executive Summary
The New Drug Advisory Committee said the number of patients enrolled in Pfizer’s Xeljanz trials was not statistically significant to recommend marketing authorization.